Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / Innoviva, Royalty, GSK, Theravance Biopharma 
Welcome,         Profile    Billing    Logout  

12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma
NCT05535972: To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD

Completed
4
460
RoW
FF/UMEC/VI, TRELEGY ELLIPTA
GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
09/23
09/23
Sundial-COPD, NCT05292053: Outcomes of Once-Daily ICS/LABA/LAMA Plus PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations

Not yet recruiting
4
80
US
TRELEGY ELLIPTA 100Mcg-62.5Mcg-25Mcg/Actuation Powder for Inhalation
Baylor Research Institute
Copd
08/23
09/23
ANTES B+, NCT06282861: Clinical Trial

Recruiting
4
1028
Europe
Trelegy Ellipta 100/62.5/25Mcg Inh 30D, LABA/LAMA/ICS, Brimica, LABA/LAMA, Duaklir, Ultibro, Ulunar, Xoterna, Anoro, Laventair, Spiolto Respimat, Yanimo, Foradil, LABA, Broncoral, Formoterol stada, Oxis, Formatris, Formoterol Aldo, Onbrez, Oslif, Hirobriz, Striverdi, Beglan, Betamican, Inaspir, Serevent, Soltel, Eklira, LAMA, Bretaris, Seebri, Tovanor, Enurev, Spiriva, Tavulus, Sirkava, Braltus, Gregal, Incruse, Rolufta
Fundacio Privada Mon Clinic Barcelona, GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
09/25
09/25
NCT06372496: Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma

Recruiting
4
1136
Canada, Japan, US, RoW
Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate, Inhaled corticosteroids/long-acting beta-2 agonists
GlaxoSmithKline
Asthma
03/26
03/26
NCT04923347: A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Completed
4
229
RoW
FF/UMEC/VI, ELLIPTA
GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
03/24
03/24
2013-003075-35: A 12 month study to compare FF/UMEC/VI with FF/VI and UMEC/VI in patients with Chronic Obstructive Pulmonary Disease(COPD) and a history of COPD exacerbation

Ongoing
3
1000
Europe, RoW
Fluticasone Furoate/Umeclidinium/Vilanterol Trifenatate, Fluticasone Furoate/Vilanterol Trifenatate, Umeclidinium/Vilanterol Trifenatate, GSK2834425 (GW685698/GSK573719/GW642444), GW685698/GW642444, GSK573719/GW642444, Relvar Ellipta, Relvar Ellipta
GlaxoSmithKline Research & Development Ltd, GlaxoSmithKline, S.A., GlaxoSmithKline, Research and Development Ltd
Chronic Obstructive Pulmonary Disease (COPD)
 
 
2013-003073-10: A 24 week study (with an extension to 52 weeks in a proportion of subjects) to compare the safety and effectiveness of FF/UMEC/VI with budesonide/formoterol in subjects with COPD Studio di 24 settimane (con estensione a 52 settimane in un sottogruppo di soggetti) per confrontare la sicurezza e l’efficacia di FF/UMEC/VI vs. budesonide/formoterolo in soggetti con broncopneumopatia cronica ostruttiva.

Ongoing
3
200
Europe
Fluticasone Furoate/Umeclidinium/Vilanterol, SALBUTAMOLO, GSK2834425, SB-240563, Symbicort Turbohaler 400 micrograms/12 micrograms/inhalation, inhalation powder, VENTOLIN SOSP INAL 200D 100MCG, Symbicort Turbohaler 400 micrograms/12 micrograms/inhalation, inhalation powder, VENTOLIN SOSP INAL 200D 100MCG
GlaxoSmithKline Research and Development, GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
 
 
2017-001532-19: An open-label study to compare the effectiveness of FF/UMEC/VI using the Connected Inhaler System with FP/SAL plus tiotropium in participants with inadequately controlled asthma

Not yet recruiting
3
1006
Europe
Fluticasone Furoate/Umeclidinium/Vilanterol, (Seretide Accuhaler/DISKUS), Spiriva Respimat, GW685698/GSK573719/GW642444, R03AK06, Inhalation powder, pre-dispensed, Inhalation solution, Trelegy Ellipta, Seretide Accuhaler/Diskus, 250/50 mcg or 500/50mcg, Spiriva Respimat
GlaxoSmithKline Research & Development Ltd, GSK
Inadequately controlled asthma, Inadequately controlled asthma, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
NCT06474039: The Efficacy of Fluticasone Furoate/Vilanterol/Umeclidinium Compared With Vilanterol/Umeclidinium in Reducing Air Trapping and Airway and Blood Cytokine Levels in COPD

Not yet recruiting
3
50
NA
Trelegy or Anoro
Mahidol University
COPD
06/26
12/26
NCT04937387: Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma

Recruiting
3
356
RoW
FF/VI, FF/UMEC/VI, ELLIPTA
GlaxoSmithKline
Asthma
09/24
09/24
NCT05757102: A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

Recruiting
3
292
US, RoW
FF/UMEC/VI, ELLIPTA, FF/VI
GlaxoSmithKline
Asthma
01/27
01/27
ETHA, NCT04651777: Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma

Active, not recruiting
3
31
Canada
FF/UMEC/VI, Trelegy
Dr. Grace Parraga, GlaxoSmithKline
Asthma
08/23
12/24

Download Options